(Q38071391)

28 August 2017

1 reference

title

New therapeutic strategies in HCV: second-generation protease inhibitors (English)

1 reference

28 August 2017

Virginia C Clark

1

1 reference

28 August 2017

Joy A Peter

series ordinal

2

1 reference

28 August 2017

David R Nelson

series ordinal

3

1 reference

28 August 2017

publication date

1 February 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

33 Suppl 1

1 reference

28 August 2017

page(s)

80-84

1 reference

Boceprevir for untreated chronic HCV genotype 1 infection

28 August 2017

cites work

1 reference

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

Telaprevir for retreatment of HCV infection

21 January 2018

1 reference

Boceprevir for previously treated chronic HCV genotype 1 infection

21 January 2018

1 reference

Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial

21 January 2018

1 reference

Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study

21 January 2018

1 reference

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

21 January 2018

1 reference

Preliminary study of two antiviral agents for hepatitis C genotype 1.

21 January 2018

1 reference

MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants

21 January 2018

1 reference

Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/LIV.12061

1 reference

28 August 2017

1 reference